The Val158Met Polymorphism of the Catechol-O-methyltransferase Gene is Associated with the PSA-Progression-Free Survival in Prostate Cancer Patients Treated with Estramustine Phosphate

Article ID	Journal	Published Year	Pages	File Type
9319975	European Urology	2005	8 Pages	PDF

Abstract

The Val158Met polymorphism of COMT is associated with the PSA-progression-free rate of EMP-treated patients in prostate cancer.

Keywords

EOM 2-Methoxyestradiol COMT RFLP HWE PSA Catechol-O-methyltransferase EMP EAM Estramustine phosphate Estramustine Hardy-Weinberg equilibrium val Prostate cancer confidence interval Methionine MET hazard ratio odds ratio Valine prostate-specific antigen restriction fragment length polymorphism Single nucleotide polymorphism Androgen Receptor

Related Topics

Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health

Preview

The Val158Met Polymorphism of the Catechol-O-methyltransferase Gene is Associated with the PSA-Progression-Free Survival in Prostate Cancer Patients Treated with Estramustine Phosphate

Authors

Motofumi Suzuki, Mohammed Rafiqul Islam Mamun, Kazuo Hara, Takeshi Ozeki, Yasuhiko Yamada, Takashi Kadowaki, Hidetoshi Honda, Yoshitsugu Yanagihara, Yoichi Minagawa Ito, Shuji Kameyama, Nobutaka Ohta, Takayuki Hosoi, Tomio Arai, Motoji Sawabe,